Decoy Therapeutics corrects warrant inducement release, says new warrants exercisable on issuance
Bitget2026/09/22 22:15- Decoy Therapeutics corrected a Sept. 22, 2026 release on its warrant inducement transaction.
- New unregistered warrants for up to 2,368,868 shares are not subject to stockholder approval.
- Warrants will become exercisable immediately upon issuance, not upon any stockholder vote.
- New Warrants will expire five years from the issuance date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan Reveals the Critical Price Level for Bitcoin Miners
Altman: Safety comes first, no IPO timetable, postponing the release of GPT-6.1 Astra out of extreme caution
OpenAI CEO Altman stated that the IPO may only be considered after the company gains a clearer understanding of how to safely manage the "next-level AI." The delay in launching GPT-6.1 Astra is because the model did not meet some of the company’s evaluation criteria for safety; this decision was made "out of an abundance of caution" rather than due to any major incident. He also noted that Nvidia’s safety systems for AI are not a "complete solution;" AI is more of a scientific problem than an engineering one.
SOS says private placement closes under securities purchase agreement
Talen names Terry Nutt CEO effective Jan. 1, 2027; Mac McFarland retires at year-end
Crypto prices
More
